---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic impact of diagnostic testing"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic impact of diagnostic testing. Topics: Medicare national average office-based payment for retinal imaging, 2025 and 2026; Coding of multimodal imaging for geographic atrophy; Diagnostic imaging at the index diagnosis: Medicare Advantage claims; Diagnostic tests as the main driver of direct ophthalmic costs. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Medicare national average office-based payment for retinal imaging, 2025 and 2026

| CPT code | 2025 non-facility total RVUs | 2026 non-facility total RVUs | 2025 non-facility pay | 2026 non-facility pay | Change in non-facility pay, 2025 to 2026 |
| --- | --- | --- | --- | --- | --- |
| 92134 (OCT, retina) | “0.97” | “0.98” | “$31.38” | “$32.73” | “4.32%” |
| 92137 (OCT angiography, retina) | “1.76” | “1.79” | “$56.93” | “$59.79” | “5.02%” |
| 92250 (fundus photography) | “1.1” | “1.11” | “$35.58” | “$37.07” | “4.20%” |
| 92235 (fluorescein angiography) | “4.72” | “4.86” | “$152.68” | “$162.33” | “6.32%” |

Source: [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)

> “National average Medicare payment w/o geographic adjustments”
> “Centers for Medicare & Medicaid Services (Updated November 3, 2025)”

Source: [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)

<a id="topic-2.2.1.8.4-2"></a>

### Coding of multimodal imaging for geographic atrophy

> “The most common imaging for GA includes color fundus photography, fundus autofluorescence (FAF), near-infrared reflectance (NIR) imaging, optical coherence tomography (OCT) and OCT-angiography (OCT-A). Color fundus photography, FAF and NIR imaging all fall under the same CPT code of 92250 (Fundus photography with interpretation and report). This is a bilateral code, so it is used for imaging one eye or both.”
> “It is also important to note that fundus photography is mutually exclusive with code 92134 for OCT/SCODI (scanning computerized ophthalmic diagnostic imaging of the retina), meaning photography and OCT cannot be billed on the same day for GA. In addition, most insurances limit OCT to payments no more than twice per year.”
> “However, imaging like this can only be repeated and billed if it is necessary to assess disease progression or the advent of new disease, or when planning additional treatments.”

Source: [Legge (2024)](https://optometricmanagement.com/issues/2024/may/coding-and-billing-for-geographic-atrophy/)

<a id="topic-2.2.1.8.4-3"></a>

### Diagnostic imaging at the index diagnosis: Medicare Advantage claims

| Diagnostic procedure received on index date | Participants with GA, n (%) |
| --- | --- |
| Any of the procedures below | “6,968 (73.3)” |
| OCT | “5,042 (53.0)” |
| Fundus photography | “2,039 (21.4)” |
| Fluorescein angiography | “600 (6.3)” |
| Fluorescein and indocyanine-green angiography at the same time | “97 (1.0)” |

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

> “The specialty of the GA diagnosing provider was determined using National Provider Identifiers, and diagnostic imaging procedures used for confirming GA diagnosis were identified using Current Procedural Terminology codes”
> “Among individuals with GA, initial diagnosis was primarily by an ophthalmologist (58.6%) followed by an optometrist (30.9%).”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.8.4-4"></a>

### Diagnostic tests as the main driver of direct ophthalmic costs

> “A variety of tests were conducted at GA diagnosis; the most common ones (used in the 98 patients initially diagnosed with bilateral GA) were distance VA (86.7%), dilated eye examination (82.7%), optical coherence tomography (OCT; 81.6%), intraocular pressure (IOP; 67.3%), and fundus autofluorescence (FAF; 44.9%).”
> “Similar to the UK cohort study, direct HCRU in our study accounted for the majority of the mean annual total costs (88%; €1772), with diagnostics tests and procedures being the main driver (€1071 per patient).”

Source: [Patel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6955611/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
